ArthNow Logo
ArthNow
•3 min read•
✦Reported by Financial Express

Paytm, Pine Labs, One Mobikwik shares fall nearly 9% on UPI MDR rollout delay

Paytm, Pine Labs, One Mobikwik shares fall nearly 9% on UPI MDR rollout delay
Source: Financial Express

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓Shares of Paytm, Pine Labs, and One Mobikwik fell after news that the UPI MDR rollout got delayed.
  • ✓The introduction of MDR is likely pushed beyond assembly elections in five states during early 2027.
  • ✓One Mobikwik shares fell nearly 9%, while Paytm and Pine Labs also saw their prices drop.

Story at a Glance

Category
Indian Markets
Reported By
Financial Express
Reading Speed
3 Minute(s)
Market Focus
India Economy

The share price of Paytm operator, One 97 Communications, plummeted nearly 7% to a low of Rs 1,760 apiece. The Pine Labs share price plunged around 6% to a low of Rs 160, and One Mobikwik Systems share price fell nearly 9% to Rs 206.61 apiece.

UPI MDR rollout deferred

According to the report, the introduction of MDR is likely to be pushed beyond the assembly elections due in five states in the first half of 2027. These states are Uttar Pradesh, Punjab, Uttarakhand, Goa, and Manipur.

The rollout of MDR could even be deferred until after the UP elections if an agreement is not reached earlier, the report said, citing a senior industry official. The official described this as the 'worst-case scenario' rather than the most likely outcome.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

Financial Express

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.